布地奈德缓释胶囊(Tarpeyo)的副作用和不良反应

Although budesonide extended-release capsules (Tarpeyo) can produce the expected therapeutic effects, they may also cause some adverse effects. Not all side effects may occur, but when they do, they may require medical intervention.

Side effects of Budesonide extended-release capsules (Tarpeyo) that seek medical attention immediately

1. Common side effects

Bruises, chills, colds, coughs, diarrhea, fever, general malaise or feeling of illness, headache, hoarseness, joint pain, loss of appetite, muscle aches, nausea, runny nose, tremors, sneezing, sore throat, sweating, sleep disorders, unusual tiredness or weakness, and vomiting.

2. Rare side effects

Bladder pain, bleeding after defecation, skin blistering, scabs, irritation, itching or redness, hematuria or cloudy urine, blurred vision, burning sensation during urination, burning sensation, ant crawling sensation, numbness, pins and needles, vision changes, Chest pain or tightness, expectoration, decreased urine output, diarrhea, difficulty breathing or labored breathing, difficulty or pain when urinating, dizziness, dry mouth, eye pain, fast, irregular, strong heartbeat or pulse, feeling of fever, heartburn, increased physical activity, increased thirst, and frequent nocturia.

Irregular heartbeat, low back or flank pain, mood changes, nervousness, pain or discomfort in the chest, upper abdomen, or throat, pinpoint red or purple spots on the skin, pulsating sensation in the ears, rectal bleeding, redness of the face, neck, arms, and occasionally upper chest, seizures, severe constipation, tremors of the legs, arms, hands, or feet.

Chills, rash, scabs, scaling and oozing, slow or fast heart rate, stomach cramps or pain, sweating, swelling of legs and feet, facial swelling or puffiness, sleep disturbance, uncomfortable swelling around the anus, upper abdominal or stomach pain, waking up at night to urinate, weight gain or loss.

The pictures come from public channels (such as the official website of the FDA, the official website of the original drug manufacturer, etc.) and are for reference only.

Other side effects of Budesonide extended-release capsules (Tarpeyo)

Some side effects may occur that usually do not require medical attention. These side effects may gradually disappear as your body adjusts to the medication. In addition, health care professionals may be able to tell patients about ways to prevent or lessen certain side effects.

Consult your doctor immediately about the side effects of Budesonide extended-release capsules (Tarpeyo)

1. Common side effects

Back pain, belching, skin blemishes, heartburn, indigestion, pain or tenderness around the eyes and cheek bones, acne, moon face, stomach discomfort or discomfort, and nasal congestion.

2. Less common side effects

Pus accumulation, agitation, bloating or fullness, hearing changes, cracked, dry or flaky skin, cracked skin at the corners of the mouth, difficulty defecating, difficulty moving, dizziness, ear discharge, ear pain or ear pain, excess gas in the stomach or intestines, fat pads between shoulders (buffalo back), and a sense of constant movement of oneself or the surrounding environment.

Increased appetite, increased body hair (especially on the face), fatigue, memory loss, hair loss or thinning hair, muscle stiffness, tension, joint pain, swelling or redness, flatulence, stomach pressure, memory problems, red, swollen or painful tongue, dizziness, drowsiness or unusual sleepiness, pain or redness around fingernails, abdominal or stomach swelling, joint swelling, and uterine bleeding between menstruation.

Side Effect Management for Healthcare Professionals

1. Overall Adverse Events

The most common adverse events of inhaled administration include nasopharyngitis, nasal congestion, pharyngitis, rhinitis, and oral candidiasis. Common adverse events with oral and rectal administration include headache, nausea, abdominal pain, and fatigue. Due to the nature of its mode of administration (inhalation, gastrointestinal protective oral formulations, and rectal enemas), it has a low potential to cause systemic adverse effects of glucocorticoids.

2. Respiratory system

(1), very common (≥10%): respiratory tract infection (up to 13%).

(2) Common (1%-10%): nasopharyngitis, nasal congestion, pharyngitis, allergic rhinitis, viral upper respiratory tract infection, epistaxis, cough, dysphonia, and hoarseness.

(3). Incidence not reported: bronchitis, dyspnea, pharyngeal disorder, pneumonia.

(4). Post-marketing reports: Throat irritation, sinusitis.

2. Endocrine system

(1), common (1%-10%): reduced blood cortisol, moon face.

(2), rare (0.1%-1%): hirsutism, Cushing's syndrome.

(3). Incidence not reported: intermenstrual bleeding, menstrual irregularity, hypothalamic-pituitary-adrenal (HPA) axis suppression, death caused by adrenal insufficiency.

(4). Post-marketing report: Adrenocortical insufficiency.

3. Immune system

(1). Common (1%-10%): oral candidiasis.

(2). Incidence not reported: immunosuppression, abscess, bronchospasm in patients with severe milk protein allergy.

4. Gastrointestinal tract

(1), very common (≥10%): nausea (up to 13%); abdominal pain (21%).

(2), common (1%-10%): viral stomach Enteritis, gastrointestinal mucosal candidiasis, epigastric pain, flatulence, abdominal fullness, constipation, indigestion, vomiting, diarrhea, throat pain/irritation, dry mouth, abnormal taste, rectal discomfort, rectal bleeding, ulcerative colitis, rectal burning or pain.

(3). Incidence not reported: anal discomfort, enteritis, epigastric pain, gastrointestinal fistula, glossitis, hemorrhoids, intestinal obstruction, tongue edema, tooth discomfort.

(4). Post-marketing report: pancreatitis.

5. Nervous system

(1), very common (≥10%): headache (up to 28%).

(2), common (1%-10%): dizziness.

(3), rare (0.1%-1%): olfactory disorder.

(4). Very rare (<0.01%): pseudotumor cerebri (including papilledema).

(5). Incidence not reported: hyperkinesia, paresthesia, tremor, drowsiness.

(6). Post-marketing report: Benign intracranial hypertension.

6. Mental system

(1) Common (1%-10%): mood changes, sleep changes, insomnia.

(2). Incidence not reported: amnesia.

(3) Post-marketing reports: psychosis, depression, aggressive reactions, irritability, nervousness, restlessness, anxiety, and mood swings.

7. Anaphylaxis

(1) Incidence not reported: allergic reactions, including anaphylaxis, rash, contact dermatitis, urticaria, angioedema, and bronchospasm.

(2) Post-marketing reports: cough, stridor, bronchospasm.

8. Musculoskeletal system

(1). Very common (≥10%): muscle spasm (12%).

(2). Common (1%-10%): joint pain and back pain.

(3), very rare (<0.01%): osteoporosis, aseptic necrosis of bone (femoral and humeral head).

(4). Incidence not reported: decreased bone density, arthritis, myalgia, growth inhibition.

9. Cardiovascular system

(1), very common (≥10%): hypertension (12%), peripheral edema (17%).

(2). Common (1%-10%): fluid retention, palpitations.

(3). Incidence not reported: tachycardia, chest pain, flushing.

10. Metabolic system

Incidence not reported: weight gain, increased appetite, hypokalemia.

11. Blood system

(1), common (1%-10%): leukocytosis.

(2), rare (0.1%-1%): anemia.

(3), rare (0.01%-0.1%): eosinophilia, Churg-Strauss syndrome.

12. Eyes

(1) Common (1%-10%): conjunctivitis.

(2). The incidence rate is not reported: eye abnormalities and abnormal vision.

(3). Post-marketing reports: glaucoma, cataracts, increased intraocular pressure.

13. Genitourinary system

(1). Common (1%-10%): urinary tract infection, candidiasis.

(2). The incidence rate is not reported: dysuria, frequent urination, and nocturia.

14. Skin

(1), very common (≥10%): acne (11%).

(2) Common (1%-10%): rash, contact dermatitis, eczema, pustular rash, pruritus, purpura.

(3), very rare (<0.01%): allergic rash, red streaks, petechiae, ecchymosis, delayed wound healing.

(4). Incidence not reported: facial edema, alopecia, dermatitis, eczema, skin discomfort, increased sweating, purpura.

(5). Post-marketing report: skin bruises.

15. Liver

Rare (0.1%-1%): elevated liver enzymes.

16. Others

(1), common (1%-10%): otitis media, fatigue, earache

(2), incidence not reported: fatigue, malaise, fever, flu-like symptoms, dizziness.

The above content only reflects the range of side effects of budesonide extended-release capsules (Tarpeyo) in overseas registered countries. It does not represent the approved use range in mainland China. Please do not make any treatment decisions based on this.